Increased Serum Levels of Inflammatory Markers in Chronic Institutionalized Patients with Schizophrenia

Activation of the cytokine systems may be involved in the neuropathological changes occurring in the central nervous systems of schizophrenic patients. However, associations between the levels of cytokines and the severity of symptoms have not been completely established. Objective: It was the aim of this study to evaluate serum levels of tumor necrosis factor (TNF)-α and their soluble receptors (sTNFR) in schizophrenic patients and healthy controls. Methods: Forty male institutionalized schizophrenic patients (mean age ± SD, 52.3 ± 9.9 years) and 20 asymptomatic matched controls were recruited. The severity of symptoms was assessed using the Brief Psychiatric Rating Scale, the Positive and Negative Syndrome Scale and the Abnormal Involuntary Movement Scale. Serum levels of cytokines were measured by ELISAs. Results: Serum levels of sTNFR1 and sTNFR2 were increased in schizophrenic patients when compared with controls (all p < 0.05), but there was no difference in TNF-α levels. There was no correlation between the length of disease/hospitalization or the severity of symptoms and the serum levels of these molecules. Conclusion: Inflammatory markers are increased in schizophrenia but they do not correlate with symptom severity.

[1]  Z. Herman,et al.  Cytokines in schizophrenia and the effects of antipsychotic drugs , 2006, Brain, Behavior, and Immunity.

[2]  M. Teixeira,et al.  Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment , 2006, Inflammation Research.

[3]  M. Schwarz,et al.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission , 2006, Neurotoxicity Research.

[4]  M. Talkowski,et al.  A comprehensive genetic association and functional study of TNF in schizophrenia risk , 2006, Schizophrenia Research.

[5]  J. Gilmore,et al.  Maternal poly I:C exposure during pregnancy regulates TNFα, BDNF, and NGF expression in neonatal brain and the maternal–fetal unit of the rat , 2005, Journal of Neuroimmunology.

[6]  M. Schwarz,et al.  Psychotropic Effects of COX-2 Inhibitors - A Possible New Approach for the Treatment of Psychiatric Disorders , 2004, Pharmacopsychiatry.

[7]  S. Tsai,et al.  No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine , 2003, Schizophrenia Research.

[8]  M. Rietschel,et al.  Association of tumor necrosis factor alpha gene -G308A polymorphism with schizophrenia , 2003, Schizophrenia Research.

[9]  N. Hayward,et al.  Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia‐Pacific region , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[10]  K. Labuzek,et al.  Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-α and nitric oxide by rat microglial cells , 2003, Neurochemistry International.

[11]  D. Sredni-Kenigsbuch.  TH1/TH2 CYTOKINES IN THE CENTRAL NERVOUS SYSTEM , 2002, The International journal of neuroscience.

[12]  T. Bayer,et al.  Review of Immunological and Immunopathological Findings in Schizophrenia , 2001, Brain, Behavior, and Immunity.

[13]  J. Lieberman,et al.  Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia , 2001, Biological Psychiatry.

[14]  A. Madej,et al.  Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia , 2001, Schizophrenia Research.

[15]  D. Remick,et al.  Cytokines and the brain: implications for clinical psychiatry. , 2000, The American journal of psychiatry.

[16]  D. Dries,et al.  Chlorpromazine modulates cytokine expression in the liver and lung after burn injury and endotoxemia. , 2000, The Journal of trauma.

[17]  M. Schwarz,et al.  The Immune System and Schizophrenia: An Integrative View , 2000, Annals of the New York Academy of Sciences.

[18]  M. Schwarz,et al.  The role of immune function in schizophrenia: an overview , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[19]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. , 1999, Journal of psychiatric research.

[20]  M. Hurme,et al.  Polymorphisms of the interleukin-1 gene complex in schizophrenia , 1999, Molecular Psychiatry.

[21]  J. V. D. van der Meer,et al.  Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. , 1998, Critical care medicine.

[22]  J. Licinio,et al.  Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. , 1998, Seminars in oncology.

[23]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. , 1997, The American journal of psychiatry.

[24]  J. Pelletier,et al.  Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha. , 1997, The Journal of rheumatology.

[25]  J. Mege,et al.  A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? , 1997, Schizophrenia Research.

[26]  M. Maj,et al.  Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment , 1997, Psychiatry Research.

[27]  M. Netea,et al.  Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. , 1995, The Journal of infectious diseases.

[28]  T. Cooper.  Department of Health, Education, and Welfare. , 1976, Military medicine.

[29]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[30]  R. Pioli,et al.  Association between −G308A tumor necrosis factor alpha gene polymorphism and schizophrenia , 2001, Molecular Psychiatry.

[31]  A. Madej,et al.  Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. , 2001, Schizophrenia research.

[32]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[33]  J. Mege,et al.  A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? , 1997, Schizophrenia Research.

[34]  G. Fantuzzi,et al.  Chlorpromazine inhibits tumour necrosis factor synthesis and cytotoxicity in vitro. , 1995, Immunology.

[35]  K. Tracey,et al.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.

[36]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.